Cargando…

A novel 7 RNA-based signature for prediction of prognosis and therapeutic responses of wild-type BRAF cutaneous melanoma

BACKGROUND: The prognosis of wild-type BRAF cutaneous melanoma (WT Bf-CM) patients remains poor due to the lack of therapeutic options. However, few studies have investigated the factors contributing to the prognosis of WT Bf-CM patients. METHODS: In this paper, we proposed and validated a novel 7-R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Ruizheng, Liu, Yaozhong, Lei, Cheng, Tang, Zhenwei, Lu, Lixia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233353/ https://www.ncbi.nlm.nih.gov/pubmed/35751033 http://dx.doi.org/10.1186/s12575-022-00170-2

Ejemplares similares

The Driverless Triple-Wild-Type (BRAF, RAS, KIT) Cutaneous Melanoma: Whole Genome Sequencing Discoveries
por: Pipek, Orsolya, et al.
Publicado: (2023)

Autophagy in BRAF-mutant cutaneous melanoma: recent advances and therapeutic perspective
por: Fratta, Elisabetta, et al.
Publicado: (2023)

BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population
por: Meevassana, Jiraroch, et al.
Publicado: (2022)

Using Immune-Related lncRNA Signature for Prognosis and Response to Immunotherapy in Cutaneous Melanoma
por: Xue, Ling, et al.
Publicado: (2021)

Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma
por: Xu, Yujian, et al.
Publicado: (2022)

Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas
por: Edmunds, S C, et al.
Publicado: (2003)

A Novel Pyroptosis-Related lncRNA Signature for Predicting the Prognosis of Skin Cutaneous Melanoma
por: Xie, Jiaheng, et al.
Publicado: (2021)

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
por: Del Curatolo, Anais, et al.
Publicado: (2018)

BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib
por: Ranzani, Marco, et al.
Publicado: (2015)

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
por: Robert, Caroline, et al.
Publicado: (2020)

The Transcriptional Landscape of BRAF Wild Type Metastatic Melanoma: A Pilot Study
por: Lastraioli, Elena, et al.
Publicado: (2022)

Senescence-Related lncRNA Signature Predicts Prognosis, Response to Immunotherapy and Chemotherapy in Skin Cutaneous Melanoma
por: Lin, Kefan, et al.
Publicado: (2023)

Pyroptosis-Related Gene Signatures Can Robustly Diagnose Skin Cutaneous Melanoma and Predict the Prognosis
por: Ju, Anji, et al.
Publicado: (2021)

A Necroptosis-Related Gene Signature to Predict the Prognosis of Skin Cutaneous Melanoma
por: Xie, Yihui, et al.
Publicado: (2022)

Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature
por: Gençler, Bilgen, et al.
Publicado: (2016)

Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients
por: Zhou, Sarah, et al.
Publicado: (2021)

Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids
por: Koroknai, Viktoria, et al.
Publicado: (2020)

Construction of five cuproptosis-related lncRNA signature for predicting prognosis and immune activity in skin cutaneous melanoma
por: Yang, Xiaojing, et al.
Publicado: (2022)

Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma
por: Wu, Xiaowen, et al.
Publicado: (2017)

A novel pyroptosis-associated gene signature for immune status and prognosis of cutaneous melanoma
por: Wu, Zhengyuan, et al.
Publicado: (2021)

m5C-Related Signatures for Predicting Prognosis in Cutaneous Melanoma with Machine Learning
por: Huang, Maoxin, et al.
Publicado: (2021)

Prediction of clinical prognosis in cutaneous melanoma using an immune-related gene pair signature
por: Yang, Yu, et al.
Publicado: (2021)

Ferroptosis-Related Gene Signature Predicts the Prognosis of Skin Cutaneous Melanoma and Response to Immunotherapy
por: Xu, Ziqian, et al.
Publicado: (2021)

Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma
por: Liu, Da, et al.
Publicado: (2023)

Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2018)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
por: Nepote, Alessandro, et al.
Publicado: (2022)

Identification of m7G-associated lncRNA prognostic signature for predicting the immune status in cutaneous melanoma
por: Rong, Jielin, et al.
Publicado: (2022)

Development of anoikis-related long non-coding RNA signature associated with prognosis and immune landscape in cutaneous melanoma patients
por: Zhong, Like, et al.
Publicado: (2023)

Development and validation of an m6A RNA methylation regulator-based signature for the prediction of prognosis and immunotherapy in cutaneous melanoma
por: Li, Tingting, et al.
Publicado: (2023)

Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells
por: Garay, Tamás, et al.
Publicado: (2015)

Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma
por: Falkenius, Johan, et al.
Publicado: (2017)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
por: Tahiri, Andliena, et al.
Publicado: (2013)

A Novel Necroptosis-Related Gene Signature in Skin Cutaneous Melanoma Prognosis and Tumor Microenvironment
por: Song, Binyu, et al.
Publicado: (2022)

A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma
por: Bhandaru, Madhuri, et al.
Publicado: (2014)

Epigenetic Changes of EGFR play an important role in BRAF inhibitor Resistant Cutaneous Melanomas
por: Wang, Jinhua, et al.
Publicado: (2014)

Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
por: Das, Ishani, et al.
Publicado: (2019)

Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients
por: Frankel, Arthur E., et al.
Publicado: (2017)

The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma
por: Sabbah, Malak, et al.
Publicado: (2023)

Leveraging a disulfidptosis-related signature to predict the prognosis and immunotherapy effectiveness of cutaneous melanoma based on machine learning
por: Zhao, Yi, et al.
Publicado: (2023)

Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
por: Vanni, Irene, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a6is7h73g2dus5k9sttshic77l